Genetic score may guide breast cancer prevention choices

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women \>= 35 years old and =\< 75 years old with at least one of the following: * A National Cancer Institute (NCI)-BCRAT 5 year risk of \>= 3% which corresponds to the level in which there is moderate evidence of treatment benefit outweighing risk according to the United States (US) Preventative Services Task Force * IBIS (Tyrer-Cuzik) score for the 10 year risk of breast cancer of \>= 5% * History atypical ductal hyperplasia or atypical lobular hyperplasia with a BCRAT \>= 3% or IBIS \>= 5% * History of lobular carcinoma in situ with a BCRAT \>= 3% or IBIS \>= 5% OR * Women \>= 18 years old or =\< 75 years old with a BRCA 1 or 2 mutation, CHEK 2, PALB 2, ATM, or other hereditary breast mutation carrier per investigator * Willing and able to provide an email address to receive study surveys * Able to participate in all aspects of the study * Understand and sign the study informed consent Exclusion Criteria: * Women whose BCRAT falls below the threshold (\<3 % 5 year risk) of moderate benefit according to the US Preventative Task Force AND Women whose IBIS score is \<8% for the 10 year risk * Women with known contra-indications to Tamoxifen, raloxifene ,exemestane, or anastrazole * Current or prior use of Tamoxifen, raloxifene, exemestane or anastrazole * Unable to give informed consent * Prior history of invasive breast cancer, ductal carcinoma in situ or other breast cancers * At high risk due to prior radiation therapy to the chest * Women who are pregnant or breastfeeding * Prior risk reducing or prophylactic mastectomy * Unwilling or unable to provide an email address for study surveys to be sent to * Subject has a known history or any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence